Novartis Ag

Merck Sharp + Dohme Corp.

Cubist Pharmaceuticals, Incorporated

Sudhakar Devidasrao Garad

Stephen Paul Collingwood

Urs Baettig

Simon James Watson

Neil John Press

Brian Cox

You Seok Hwang

Dimitris Papoutsakis

Jian-Qiao Gu

Hyungchul Kim

Valdas Jurkauskas

Frank Stowasser

Kristos Adrian Moshos

Markus Bänziger

Pradip M Pathare

Anasuya Ashok Ghosh

Jacob P Sizemore

Carlos Lopez

Jay Parthiban Lakshman

Lipa Shah

Radha Vippagunta

Akash Jain

Markus Baenziger

This disclosure relates to salt forms of ceftolozane, processes for making these salt forms, and compositions comprising the same. Also disclosed are stabilized compositions of ceftolozane. Provided herein are salt forms of ceftolozane, processes for making these salt forms and compositions comprising the same. The salt forms provided herein include ceftolozane bromide, ceftolozane edisylate, ceftolozane mesylate, ceftolozane chloride, ceftolozane sulfate, ceftolozane maleate, ceftolozane phosphate, and ceftolozane ketoglutarate.

Salt forms of ceftolozane

This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions.

Crystalline form of a &#x3b2;-lactamase inhibitor

The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.

Vitamin E formulations of sulfamide NS3 inhibitors

The invention relates to particular crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, its hydrates and solvates, its salts and hydrates and solvates of its salts, certain processes for their preparation, pharmaceutical compositions containing these crystalline forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.

Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile

Compounds of Formula (I); in salt or zwitterionic form wherein R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described. 

Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists

Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists

Growing community of inventors

Cambridge, MA, United States of America

Sudhakar Devidasrao Garad